✦ LIBER ✦

Ribavirin plus interferon daily or thrice weekly in chronic hepatitis C genotype 4

✍ Scribed by Ayman Y Abdel Rahim; Mohsen Salama; Salah El-Dirini; Baher Badawy

Book ID: 119389504
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 33 KB
Volume: 95
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(00)01520-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daily interferon plus ribavirin for chro

Daily interferon plus ribavirin for chronic hepatitis C

✍ S.G. Deledda; L. Fastame; M. Maragkoudakis; M.P. Dom; D. Mors; G. Massarelh; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Efficacy and tolerability of interferon

Efficacy and tolerability of interferon (Intron a) plus ribavirin (Rebetron) administered daily for two months, then thrice weekly interferon (Intron a) plus ribavirin (Rebetron), versus standard thrice weekly administration of Rebetron for the treatment of chronic hepatitis C in patients naive to interferon therapy

✍ Michael S. Epstein; Teresa DeHaemer; Patricia M. Praschak; Robert G. Finkel; Nat 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 22 KB

Pegylated interferon plus ribavirin in c

Pegylated interferon plus ribavirin in chronic hepatitis c

✍ Bruce R. Bacon 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 38 KB

Induction treatment of chronic hepatitis

Induction treatment of chronic hepatitis C with daily interferon plus ribavirin plus amantadine is effective in non-responders to interferon plus ribavirin

✍ R. Stauber; P. Munda-Steindl; F. Hackl; K. Schüutze; C. Datz; H. Hofer; K. Hegen 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues

✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Interleukin 28B polymorphism predicts pe

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4

✍ Stella De Nicola; Alessio Aghemo; Maria Grazia Rumi; Enrico Galmozzi; Luca Valen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 1 views

Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4